{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:13:56Z","timestamp":1773814436351,"version":"3.50.1"},"reference-count":88,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Non-clear cell renal cell carcinoma (nccRCC) is an entity comprised of a heterogeneous constellation of RCC subtypes. Genomic profiling has broadened our understanding of molecular pathogenic mechanisms unique to individual nccRCC subtypes. To date, clinical trials evaluating the use of immunotherapies and targeted therapies have predominantly been conducted in patients with clear cell histology. A comprehensive review of the literature has been undertaken in order to describe molecular pathogenic mechanisms pertaining to each nccRCC subtype, and concisely summarise findings from therapeutic trials conducted in the nccRCC space.<\/jats:p>","DOI":"10.3390\/curroncol30010070","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T07:28:10Z","timestamp":1673249290000},"page":"923-937","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature"],"prefix":"10.3390","volume":"30","author":[{"given":"Alexius","family":"John","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Eastern Health, Melbourne, VIC 3128, Australia"},{"name":"Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lavinia","family":"Spain","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anis A.","family":"Hamid","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Eastern Health, Melbourne, VIC 3128, Australia"},{"name":"Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia"},{"name":"Eastern Health Clinical School, Monash University, Melbourne, VIC 3128, Australia"},{"name":"Department of Surgery, University of Melbourne, Melbourne, VIC 3010, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.14740\/wjon1279","article-title":"Epidemiology of Renal Cell Carcinoma","volume":"11","author":"Padala","year":"2020","journal-title":"World J. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2018.08.036","article-title":"Epidemiology of Renal Cell Carcinoma","volume":"75","author":"Capitanio","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nrurol.2010.46","article-title":"Epidemiology and risk factors for kidney cancer","volume":"7","author":"Chow","year":"2010","journal-title":"Nat. Rev. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/annonc\/mdz056","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Escudier","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","article-title":"The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs\u2014Part A: Renal, Penile, and Testicular Tumours","volume":"82","author":"Moch","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1159\/000495366","article-title":"IAG-N Interdisciplinary Working Group Kidney Cancer of the German Cancer Society Non-Clear Cell Renal Cell Carcinoma\u2014Pathology and Treatment Options","volume":"42","author":"Ahrens","year":"2019","journal-title":"Oncol. Res. Treat."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e001079","DOI":"10.1136\/esmoopen-2020-001079","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended 4-year follow-up of the phase III CheckMate 214 trial","volume":"5","author":"Albiges","year":"2020","journal-title":"ESMO Open"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): Extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Zarrabi, K., Walzer, E., and Zibelman, M. (2021). Immune Checkpoint Inhibition in Advanced Non-Clear Cell Renal Cell Carcinoma: Leveraging Success from Clear Cell Histology into New Opportunities. Cancers, 13.","DOI":"10.3390\/cancers13153652"},{"key":"ref_13","first-page":"327","article-title":"Papillary renal cell carcinoma: Review","volume":"39","author":"Mendhiratta","year":"2021","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1097\/01.MP.0000036346.88874.25","article-title":"Morphologic Subtyping of Papillary Renal Cell Carcinoma: Correlation with Prognosis and Differential Expression of MUC1 between the Two Subtypes","volume":"15","author":"Leroy","year":"2002","journal-title":"Mod. Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3233\/KCA-190058","article-title":"A Review of Papillary Renal Cell Carcinoma and MET Inhibitors","volume":"3","author":"Smith","year":"2019","journal-title":"Kidney Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network, Linehan, W.M., Spellman, P.T., Ricketts, C.J., Creighton, C.J., Fei, S.S., Davis, C., Wheeler, D.A., Murray, B.A., and Schmidt, L. (2016). Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N. Engl. J. Med., 374, 135\u2013145.","DOI":"10.1056\/NEJMoa1505917"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13023-020-01653-9","article-title":"Hereditary leiomyomatosis and renal cell carcinoma: A case series and literature review","volume":"16","author":"Chayed","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"686556","DOI":"10.3389\/fonc.2021.686556","article-title":"Hereditary Leiomyomatosis and Renal Cell Cancer: Recent Insights Into Mechanisms and Systemic Treatment","volume":"11","author":"Zhang","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_19","first-page":"851","article-title":"Ultrastructural appearance and cytoskeletal architecture of the clear, chromophilic, and chromophobe types of human renal cell carcinoma in vitro","volume":"142","author":"Gerharz","year":"1993","journal-title":"Am. J. Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ccr.2014.07.014","article-title":"The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma","volume":"26","author":"Davis","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"103287","DOI":"10.1016\/j.critrevonc.2021.103287","article-title":"Comprehensive review of chromophobe renal cell carcinoma","volume":"160","author":"Garje","year":"2021","journal-title":"Crit. Rev. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.clgc.2019.06.011","article-title":"Chromophobe Renal Cell Carcinoma: Results From a Large Single-Institution Series","volume":"17","author":"Casuscelli","year":"2019","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_23","first-page":"270","article-title":"Renal medullary carcinoma: A case report and brief review of the literature","volume":"14","author":"Shetty","year":"2014","journal-title":"Ochsner J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.ccell.2020.04.002","article-title":"Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma","volume":"37","author":"Msaouel","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"134","DOI":"10.15586\/jkcvhl.2015.37","article-title":"Collecting Duct Renal Cell Carcinoma Found to Involve the Collecting System During Partial Nephrectomy: A Case Report","volume":"2","author":"Harbin","year":"2015","journal-title":"J. Kidney Cancer VHL"},{"key":"ref_26","first-page":"54","article-title":"Collecting duct carcinoma of kidney","volume":"15","author":"Srigley","year":"1998","journal-title":"Semin. Diagn. Pathol."},{"key":"ref_27","first-page":"540.e13","article-title":"Collecting duct carcinoma of the kidney: Disease characteristics and treatment outcomes from the National Cancer Database","volume":"35","author":"Sui","year":"2017","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Zhang, H., Lu, X., Huang, G., Hua, M., Zhang, W., Wang, T., Huang, L., Wang, Z., Chen, Q., and Li, J. (2022). A genomic mutation spectrum of collecting duct carcinoma in the Chinese population. BMC Med. Genom., 15.","DOI":"10.1186\/s12920-021-01143-2"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41467-021-21068-9","article-title":"Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma","volume":"12","author":"Bakouny","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Pichler, R., Comp\u00e9rat, E., Klatte, T., Pichler, M., Loidl, W., Lusuardi, L., and Schmidinger, M. (2019). Renal Cell Carcinoma with Sarcomatoid Features: Finally New Therapeutic Hope?. Cancers, 11.","DOI":"10.3390\/cancers11030422"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1097\/00000478-200010000-00002","article-title":"Renal Cell Carcinoma With Rhabdoid Features","volume":"24","author":"Nappi","year":"2000","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1097\/PAS.0b013e318299f0fb","article-title":"The International Society of Urological Pathology (ISUP) Grading System for Renal Cell Carcinoma and Other Prognostic Parameters","volume":"37","author":"Delahunt","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1097\/PAS.0000000000000251","article-title":"Rhabdoid Differentiation Is Associated With Aggressive Behavior in Renal Cell Carcinoma","volume":"38","author":"Przybycin","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1016\/j.clgc.2014.08.011","article-title":"Outcome of Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium","volume":"13","author":"Kyriakopoulos","year":"2014","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1158\/1078-0432.CCR-20-2063","article-title":"Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma","volume":"27","author":"Tannir","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1200\/JCO.2019.37.15_suppl.4500","article-title":"Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate\/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study","volume":"37","author":"Rini","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"100101","DOI":"10.1016\/j.esmoop.2021.100101","article-title":"Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: Post hoc analysis of a randomized clinical trial","volume":"6","author":"Choueiri","year":"2021","journal-title":"ESMO Open"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Pandolfo, S.D., Carbonara, U., Beksac, A.T., Derweesh, I., Celia, A., Schiavina, R., Elbich, J., Basile, G., Hampton, L.J., and Cerrato, C. (2022). Microwave versus cryoablation and radiofrequency ablation for small renal mass: A multicenter comparative analysis. Minerva Urol. Nephrol., ahead of print.","DOI":"10.23736\/S2724-6051.22.05092-3"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejca.2017.03.011","article-title":"Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study","volume":"80","author":"Colomba","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/j.clgc.2016.12.024","article-title":"First-Line PAzopanib in NOn\u2013clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study","volume":"15","author":"Buti","year":"2017","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejca.2018.08.014","article-title":"Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis","volume":"104","author":"Campbell","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4103\/sajc.sajc_22_18","article-title":"Treatment outcomes of metastatic nonclear cell renal cell carcinoma: A single institution retrospective analysis","volume":"07","author":"Agarwala","year":"2018","journal-title":"South Asian J. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1470-2045(18)30907-0","article-title":"Cabozantinib in advanced non-clear-cell renal cell carcinoma: A multicentre, retrospective, cohort study","volume":"20","author":"Xie","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1002\/cam4.2222","article-title":"Survival and clinical prognostic factors in metastatic non-clear cell renal cell carcinoma treated with targeted therapy: A multi-institutional, retrospective study using the Korean metastatic renal cell carcinoma registry","volume":"8","author":"Kim","year":"2019","journal-title":"Cancer Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"S1320","DOI":"10.1016\/j.annonc.2020.10.214","article-title":"202MO Real-world outcomes of non-clear cell renal cell carcinoma: Retrospective study from tertiary cancer center in India","volume":"31","author":"Choudhary","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1158\/2326-6066.CIR-17-0475","article-title":"The Clinical Activity of PD-1\/PD-L1 Inhibitors in Metastatic Non\u2013Clear Cell Renal Cell Carcinoma","volume":"6","author":"McKay","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.clgc.2019.11.012","article-title":"Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non\u2013Clear Cell Renal Cell Carcinoma","volume":"18","author":"Gupta","year":"2019","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1634\/theoncologist.2019-0372","article-title":"Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis","volume":"25","author":"Chahoud","year":"2019","journal-title":"Oncologist"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40425-018-0319-9","article-title":"Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma","volume":"6","author":"Koshkin","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1200\/JCO.2020.38.6_suppl.640","article-title":"Safety and efficacy of immune checkpoint inhibitors (ICI) in metastatic non-clear cell renal cell carcinoma (nccRCC): An institutional experience","volume":"38","author":"Schwartzman","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1200\/JCO.2022.40.16_suppl.4545","article-title":"Outcomes with novel combinations in nonclear cell renal cell carcinoma (nccRCC): ORACLE study","volume":"40","author":"Kilari","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1093\/annonc\/mdu445","article-title":"PD-L1 expression in nonclear-cell renal cell carcinoma","volume":"25","author":"Choueiri","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"269","DOI":"10.21037\/atm.2020.02.81","article-title":"Tumor mutational burden and immune signatures interplay in renal cell carcinoma","volume":"8","author":"Yakirevich","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1470-2045(17)30516-8","article-title":"Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: A pan-cancer analysis","volume":"18","author":"Turajlic","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.20.02363","article-title":"Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma","volume":"39","author":"McDermott","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.clgc.2020.05.006","article-title":"Safety and Efficacy of Nivolumab in Patients With Advanced Non\u2013Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb\/IV CheckMate 374 Study","volume":"18","author":"Vogelzang","year":"2020","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1200\/JCO.21.02938","article-title":"Phase II Study of Nivolumab and Salvage Nivolumab\/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)","volume":"40","author":"Atkins","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e003844","DOI":"10.1136\/jitc-2021-003844","article-title":"Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: Results from the phase 3b\/4 CheckMate 920 trial","volume":"10","author":"Tykodi","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.1200\/JCO.2022.40.16_suppl.4537","article-title":"Sequential immunotherapy in rare variant renal cell carcinomafinal report of UNISoN (ANZUP 1602): Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma","volume":"40","author":"Conduit","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1046\/j.1442-2042.2002.00511.x","article-title":"Angiogenesis in renal cell carcinoma: Evaluation of microvessel density, vascular endothelial growth factor and matrix metalloproteinases","volume":"9","author":"Zhang","year":"2002","journal-title":"Int. J. Urol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fnmol.2011.00051","article-title":"PI3K\/AKT\/mTOR Pathway in Angiogenesis","volume":"4","author":"Karar","year":"2011","journal-title":"Front. Mol. Neurosci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S1470-2045(15)00515-X","article-title":"Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): A multicentre, open-label, randomised phase 2 trial","volume":"17","author":"Armstrong","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.eururo.2015.10.049","article-title":"Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non\u2013Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial","volume":"69","author":"Tannir","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/annonc\/mdx075","article-title":"Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC","volume":"28","author":"Knox","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejca.2016.08.004","article-title":"Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis","volume":"69","author":"Escudier","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1001\/jamaoncol.2022.0238","article-title":"Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma","volume":"8","author":"Procopio","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"TPS4601","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4601","article-title":"SAMETA: An open-label, three-arm, multicenter, phase III study of savolitinib + durvalumab versus sunitinib and durvalumab monotherapy in patients with MET-driven, unresectable, locally advanced\/metastatic papillary renal cell carcinoma (PRCC)","volume":"40","author":"Choueiri","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejca.2017.10.014","article-title":"Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial","volume":"87","author":"Wozniak","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1200\/JCO.2012.43.3383","article-title":"Phase II and Biomarker Study of the Dual MET\/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma","volume":"31","author":"Choueiri","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3233\/KCA-170018","article-title":"Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107","volume":"1","author":"Twardowski","year":"2017","journal-title":"Kidney Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jamaoncol.2020.2218","article-title":"Efficacy of Savolitinib vs. Sunitinib in Patients WithMET-Driven Papillary Renal Cell Carcinoma","volume":"6","author":"Choueiri","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(21)00152-5","article-title":"A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: A randomised, open-label, phase 2 trial","volume":"397","author":"Pal","year":"2021","journal-title":"Lancet"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.1200\/JCO.2020.38.15_suppl.5004","article-title":"Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer","volume":"38","author":"Srinivasan","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.4143\/crt.2019.086","article-title":"Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients","volume":"51","author":"Choi","year":"2019","journal-title":"Cancer Res. Treat."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/s41588-018-0170-4","article-title":"Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair","volume":"50","author":"Sulkowski","year":"2018","journal-title":"Nat. Genet."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.21.01944","article-title":"Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non\u2013Clear-Cell Renal Cell Carcinoma and Genomic Correlates","volume":"40","author":"Lee","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1200\/JCO.2019.37.7_suppl.545","article-title":"A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO)","volume":"37","author":"Powles","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"LBA4503","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA4503","article-title":"CALYPSO: A three-arm randomized phase II study of durvalumab alone or with savolitinib or tremelimumab in previously treated advanced clear cell renal cancer","volume":"40","author":"Powles","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.19.01882","article-title":"Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and\/or Sarcomatoid Features","volume":"38","author":"McGregor","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1200\/JCO.21.00939","article-title":"Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study","volume":"39","author":"Pal","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"64","DOI":"10.52733\/kcj19n3-a1","article-title":"Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial","volume":"19","author":"Halabi","year":"2021","journal-title":"Kidney Cancer J."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1159\/000506296","article-title":"Association between PD-L1 Expression and the Prognosis and Clinicopathologic Features of Renal Cell Carcinoma: A Systematic Review and Meta-Analysis","volume":"104","author":"Shen","year":"2020","journal-title":"Urol. Int."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Di Meo, N.A., Lasorsa, F., Rutigliano, M., Loizzo, D., Ferro, M., Stella, A., Bizzoca, C., Vincenti, L., Pandolfo, S.D., and Autorino, R. (2022). Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232214360"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00109-014-1180-z","article-title":"The role of HIF1\u03b1 in renal cell carcinoma tumorigenesis","volume":"92","author":"Gudas","year":"2014","journal-title":"J. Mol. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for Renal Cell Carcinoma in von Hippel\u2013Lindau Disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"413","DOI":"10.5732\/cjc.012.10102","article-title":"Fumarate hydratase inactivation in renal tumors: HIF1 alpha, NRF2, and \u201ccryptic targets\u201d of transcription factors","volume":"31","author":"Ooi","year":"2012","journal-title":"Chin. J. Cancer"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/1\/70\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:04:31Z","timestamp":1760119471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/1\/70"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,9]]},"references-count":88,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["curroncol30010070"],"URL":"https:\/\/doi.org\/10.3390\/curroncol30010070","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,9]]}}}